Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Intel heads into the final stretch before its Q3 earnings report with the stock down a further 3% on the week, shorts adding positions at a measured pace, and the Street anchored near neutral despite a handful of recent target upgrades.
The pullback has continued from where last week's note left off. Intel closed Tuesday at $112.49, down 3% over five days after the previous week already saw a 6.4% decline. The stock is now roughly 9% below the $123 area it briefly touched in late September. That said, the longer-term picture remains extraordinary: Intel is still up nearly 17% over the past month and has more than tripled year-to-date. The week's weakness is again stock-specific. Peers moved broadly higher: AMD gained 6.9% on the week, added 17.9%, rose 8.9%, and was broadly flat. Intel underperformed every name in its peer group.
Short positioning is rebuilding, but not aggressively. Short interest has risen 2.5% over the past week to 3.45% of free float, and is up 18.7% over the past month, continuing the slow accumulation that started in early September after the post-squeeze lows. That month-on-month build is worth watching, but the absolute level remains modest. The lending market tells the same relaxed story: availability is effectively unlimited, with over 5.2 billion shares available to borrow and cost to borrow falling sharply to 0.24%, down 40% on the week and at its lowest level in the 30-day window. The ORTEX short score is a steady 32, near the middle of its 30-day range, consistent with a market that is adding short exposure incrementally rather than pressing a conviction bet. Options positioning is equally neutral: the put/call ratio at 0.86 is fractionally below its 20-day average of 0.87, with a z-score of essentially zero. None of these signals point to a charged setup into earnings.
The Street is cautiously constructive but not aligned. Mizuho raised its target on Intel on October 6 to $114 from $92 while keeping a Neutral rating, a notable reversal from the same analyst who cut the target to $92 in early September. That reversal tracks the stock's recovery. Other recent moves have been similarly mixed: Tigress Financial raised its Buy target to $145, Northland Capital Markets upgraded to Outperform with a $120 target, and Piper Sandler initiated at Neutral with a $110 target. The consensus mean target sits at $118, implying roughly 5% upside from current levels. The bull case centres on x86 CPU demand from AI inference workloads: Q2 revenue grew 25% year on year to $16.1 billion, with Data Center and AI revenue up 59%. The bear case is foundry: external foundry customers account for roughly 0.5% of the leading-edge market, and total external foundry revenue remains below $2 billion, leaving the foundry story dependent almost entirely on internal volumes for now. Factor scores add little urgency: EPS momentum over 90 days ranks in the 86th percentile, and the days-to-cover rank is in the 91st percentile, but EV/EBIT ranks in just the 8th percentile, a reminder that valuation has re-rated sharply on a still-thin earnings base.
The most differentiated data point in the window remains the CEO buy. Lip-Bu Tan purchased $10 million of Intel stock on August 11 at $95, a discretionary open-market transaction with no 10b5-1 plan attached. The stock has since risen 18% from that level. No further insider activity of comparable significance has appeared since. Institutional flows at the top of the register have been constructive: BlackRock added 16.6 million shares in the quarter to September, Capital Research added 10.2 million, and FMR added 34.7 million, a meaningful build for a single quarter. One notable 13D/G development: The Vanguard Group filed an amended 13G in March showing its stake fell to zero from 8.11%, with Vanguard Capital Management subsequently filing a fresh 13G at 6.52% in April. The disclosure reflects a reorganisation of Vanguard's voting structure rather than an exit, but it is worth noting that stakes are as last disclosed around the 5% threshold and positions can change without a further filing.
The last two earnings prints produced consecutive double-digit declines. The July 24 Q2 result sent Intel down 8.5% on the day and 10% over the following five sessions. The prior print followed the same pattern. With Q3 results due October 22, just fifteen days away, the question is whether the same dynamic reasserts, or whether the Q2 execution on Data Center margins has shifted the calculus enough to absorb another volatile read. What to watch into October 22 is straightforward: whether short interest continues its measured monthly build toward the 4% level, whether the Mizuho target raise marks a broader analyst re-rating above $120, and whether options skew starts to shift toward more defensive positioning as the print approaches.
See the live data behind this article on ORTEX.
Open INTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
